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Abstract
We have previously developed and validated a prognostic model to predict the risk for unfavorable outcome in Dutch
adults with bacterial meningitis. The aim of the current study was to validate this model in adults with bacterial meningitis
from two developing countries, Vietnam and Malawi. Demographic and clinical characteristics of Vietnamese (n=426),
Malawian patients (n=465) differed substantially from those of Dutch patients (n=696). The Dutch model underestimated
the risk of poor outcome in both Malawi and Vietnam. The discrimination of the original model (c-statistic [c] 0.84; 95%
confidence interval 0.81 to 0.86) fell considerably when re-estimated in the Vietnam cohort (c=0.70) or in the Malawian
cohort (c=0.68). Our validation study shows that new prognostic models have to be developed for these countries in a
sufficiently large series of unselected patients.
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Introduction
Bacterial meningitis remains an important cause of morbidity
and mortality worldwide, even though effective antibiotic therapy
is available. [1–4] The most common causes are Streptococcus
pneumoniae and Neisseria meningitidis, accounting for 85% of cases in
adults. [1–4] Fatality rates in patients with meningitis caused by
these microorganisms are significant, with rates of 10% and 26%
in high-income countries and 15% and 50% in low-income
countries. [1,3,4] Of surviving patient up to 50% have neurologic
deficits, hearing loss, [5] and cognitive deficits. [6,7]
We previously developed and validated a risk score to predict
the risk for unfavorable outcome, using two cohorts of Dutch
adults with bacterial meningitis. [3,8,9] We first derived a score for
the risk for an poor outcome by performing logistic regression
analyses of data from a prospective cohort study (n=696). [3] A
key set of independent prognostic variables was selected from 22
potential predictors. A nomogram based on these key variables
was constructed to facilitate use in clinical practice. To validate
this nomogram, we used data from our randomized controlled
trial on adjunctive dexamethasone therapy in adults with bacterial
meningitis (n=301). [9] In the analysis, 6 of 22 variables that are
routinely available within 1 hour after admission were robust
enough for inclusion in the final risk score: age, heart rate,
Glasgow Coma Scale score, cranial nerve palsies, a cerebrospinal
fluid leukocyte count less than 1,000 cells/mm
3, and gram-positive
cocci in cerebrospinal fluid Gram’s stain. The concordance index
for the risk score was 0.84 (95% confidence interval, 0.80 to 0.87)
in the original cohort and 0.81 (95% confidence interval, 0.74 to
0.87) in the external validation cohort.
This simple bedside risk score is based on six variables that are
routinely collected within an hour of admission and helps
physicians to reliably stratify bacterial meningitis patients at initial
presentation with respect to the risk for an unfavorable outcome.
[8] Risk assessment can be important for physicians because of
decisions about the level of care (ward or high-care facility) but
may be even more important for informing the patient and his or
her relatives. The use of our model may also facilitate the
interpretation of future clinical studies in adults with bacterial
meningitis because the risk for adverse outcome or the effect of
therapeutic interventions is likely to vary in different patient
groups.
However, meningitis populations differ substantially depending
on the geographic area; the utility of the risk score in other parts of
the world is unknown. [1,2,4] The aim of the current study was to
assess whether this risk score has a similar predictive value in adult
meningitis populations from Vietnam and Malawi as previously
found in the Netherlands.
Methods
The Dutch risk model was developed from a series of 696
episodes of adult culture-proven community-acquired bacterial
meningitis from a nationwide prospective cohort study. [3,8,9]
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poor outcome at discharge: higher age, increased heart rate, lower
Glasgow Coma Scale score, presence of cranial nerve palsies, a
cerebrospinal fluid (CSF) leukocyte count less than 1,000 cells/
mm
3, and Gram-positive cocci in CSF Gram’s stain. Poor
outcome was defined as a score on the Glasgow Outcome Scale
(GOS) of 4 or lower assessed at discharge. The GOS is a well-
validated 5-point scale ranging from 1 (dead) to 5 (good recovery).
Further details can be found in two previous publications. [3,8]
The Vietnam cohort was a randomized controlled trial (RCT)
of adjunctive dexamethasone therapy for adults in Vietnam. [10]
Patients older than 14 years with suspected bacterial meningitis
were eligible to enter the study. Inclusion criteria were clinical
evidence of meningitis (defined as nuchal rigidity, with elevations
in the white-cell count and protein concentration in the CSF) and
at least one of the following: bacteria detected in CSF by Gram’s
or acridine orange stain; a positive CSF latex agglutination test;
pathogenic bacteria cultured from either the blood or the CSF; or
a clinical history of less than 7 days of illness, with a cloudy CSF, a
white-cell count with more than 60% neutrophils, and a ratio of
CSF to blood glucose that was less than 50%. The score on the
modified Rankin Scale (mRS) was assessed one month after
randomization; unfavorable outcome was defined as a score of 1–
5, or death. [10] Scores on the GOS were not assessed in this
study. Data were complete for all six risk score predictors in 408 of
435 Vietnamese patients (94%). Dexamethasone did not improve
the outcome overall in this study, although patients with
microbiologically proven disease appeared to benefit. We included
patients from both treatment arms.
The Malawi cohort was a RCT of adjunctive dexamethasone
therapy for adults in Malawi with bacterial meningitis. [11]
Eligible patients were 16 years or older and had suspected
meningitis in combination and either cloudy CSF, bacteria in CSF
on Gram’s staining or a CSF leukocyte count of more than 100
cells/mm
3 with .50% neutrophils. The score on the GOS was
assessed 40 days after randomization; unfavorable outcome was a
GOS score of 1–4. Data were complete for all six risk score
predictors in 349 of 465 Malawian patients (75%); data concerning
Table 1. Characteristics of adults with bacterial meningitis in the Netherlands, Vietnam, and Malawi.
Dutch cohort
(n=696)
Vietnamese cohort
(n=435) P1
Malawian cohort
(n=451) P2
Characteristics
Age, median years (IQR) 52 (32–67) 41 (17–54) ,0.0001 31 (25–38) ,0.0001
Male sex, n (%) 345 (50) 317 (73) ,0.0001 230 (49) 1.00
Prior antibiotic treatment (n) 64 (9) 238 (55) ,0.0001 123 (26) ,0.0001
HIV infected patients, n (%) 4 (,1) 2 (,1) 1.0 389 (90) ,0.0001
Admission
Heart rate, median (IQR) 100 (80–114) 92 (80–105) 0.04 100 (90–120) ,0.0002
Diastolic blood pressure, median mm Hg, (IQR) 90 (67–90) 80 (60–80) ,0.0001 70 (60–80) 0.0006
Score on GCS, mean6SD 11631 2 63 0.01 1163 0.53
Hemiparesis or monoparesis, n (%) 74 (11) 36 (9) 0.533 21 (6) 0.022
Cranial nerve palsies, n (%) 193 (28) 35 (8) ,0.0001 77 (22)* 0.0002
Cerebrospinal fluid WCC counts
median (IQR) 3000 (704–8533) 2990 (1000–7450) 0.02 480 (131–1880) (n=461) ,0.0001
,1000/mm
3, n (%) 184 (29) 106 (25) 0.161 281 (60) ,0.0001
Results Gram stain, n (%) ,0.0001 ,0.0001
Gram positive cocci 320 (49) 181 (42) 237 (54)
Gram negative cocci 225 (34) 21 (5) 8 (2)
Other bacteria 22 (3) 19 (4) 15(3)
Negative 87 (13) 211 (49) 179 (41)
Causative bacteria, n (%) ,0.0001 ,0.0001
Streptococcus pneumoniae 352 (51) 50 (12) 254 (55)
Streptocooccus suis 4( ,1) 113 (26) 0
Neisseria meningitidis 257 (37) 11 (3) 14 (3)
No bacteria cultured 3 (,1) 213 (49) 157 (34)
Median risk score (IQR) 20.95 (22.11 to 0.01) 21.51 (22.50 to 0.057) ,0.0001 20.70 (21.58 to 0.39) 0.0003
Outcome
Unfavorable outcome (GOS 1–4 or mRS 1–5), n (%) 237 (34) 210 (49) ,0.0001 296 (66) ,0.0001
Death (GOS=1), n (%) 143 (21) 28 (11) ,0.0001 249 (55) ,0.0001
Numbers are number/number assessed (percentage) or mean 6 standard deviation unless otherwise indicated. Median risk score refers to risk score published in
reference [3], P1 denotes P-value for comparison between Dutch and Vietnamese cohorts, P2 denotes P-value for comparison between Dutch and Malawian cohorts,
HIV denotes human immunodeficiency virus, BP blood pressure, GCS Glasgow Coma Scale, GOS Glasgow Outcome Scale, mRS modified Ranking Scale, CSF
cerebrospinal fluid, WBC white blood cells. * any cranial nerve palsy except VIII.
doi:10.1371/journal.pone.0034311.t001
Risk Prediction Bacterial Meningitis
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Dexamethasone did not improve the outcome in this study. We
included patients from both treatment arms.
Validation was performed by examining calibration, discrimi-
nation, and reassessing the logistic regression coefficients of
individual predictors of the Dutch model in the Vietnamese and
Malawian dataset. The original coefficients of the Dutch logistic
regression model were applied to the patients in the validation
datasets to calculate the risk score and predicted risk for each
patient. The discrimination of the nomogram model in the
validation cohorts was quantified by calculating the area under the
Receiver operating characteristic (ROC) curve based on a model
that only contained the risk score based on the Dutch coefficients.
The area under the ROC is also known as the concordance or c-
statistic. Bootstrap sampling (no. of samples 1999) was used to
obtain 95% confidence intervals of the c-statistic by taking the 2.5
th
and 97
th percentile value of the bootstrap samples. Calibration or
goodness of fit of the original prognostic model was assessed by
examining the differences in observed versus predicted probabil-
ities of unfavorable outcome across the range of predicted risk in
both the Malawi and Vietnam cohorts. If predictions from the
nomogram were consistently too high or too low, we examined
whether a change in intercept would improve the calibration. We
re-estimated the coefficients of the individual predictors of the
nomogram model in the validation cohorts and determined
whether these estimates in the validation cohort differed
significantly from the original estimates in the Dutch cohort using
the independent two-sample Z-test. All analyses were performed
using SASH software version 9.2 (SAS Institute, Cary, North
Carolina, USA).
Unfavorable outcome was defined as a score on the GOS of 4 or
lower assessed at discharge in The Netherlands and Malawi. In the
Vietnam dataset unfavorable outcome was defined as a score on
the mRS of 1–5, or death one month after randomization. In the
Vietnam dataset additional analyses were performed for mRS
scores 0–2 vs. 3–5 or death.
The original studies were approved by the research ethics
committees of the University of Malawi College of Medicine and
the Liverpool School of Tropical Medicine (Malawi study), and the
ethics committee of the Hospital for Tropical Diseases (Vietnam
study). Informed written consent was given.
Results
There were many differences in demographic and clinical
characteristics between the Dutch cohort (n=696) and the
Vietnamese (n=426) and Malawian (n=465) cohorts (Table 1).
Patients in Vietnam (median age, 43 years) and Malawi (median
age, 33 years) were younger as compared with Dutch patients
(median age, 50 years). Antibiotics were administered prior to
admission in 55% of Vietnamese patients, and in 25% and 9% of
Malawian and Dutch patients respectively (p,0.0001). Patients in
Vietnam were predominately male (84%) and those in Malawi
were almost uniformly HIV-infected (90%). CSF cultures were
negative in 49% and 34% patients from Vietnam and Malawi, as
compared ,1% in the Dutch cohort. The most common causative
bacteria were Streptococcus pneumoniae in The Netherlands (51%) and
Malawi (55%), and Streptococcus suis in Vietnam (32%). The
percentage of patients with unfavorable outcome varied between
cohorts (Netherlands, 34%; Vietnam, 49%; Malawi, 65%).
The Dutch model (original c-statistic=0.84, 95% CI 0.81–0.86)
[1] was less discriminatory in Vietnamese patients (c=0.70, 95%
Figure 1. Receiver operating characteristic curves of the final
nomogram model in the Netherlands (black), Vietnam (red),
and Malawi (green).
doi:10.1371/journal.pone.0034311.g001
Table 2. Predicted and observed percentage of patients with an unfavorable outcome across the range of predicted risk scores in
the validation cohorts for Vietnam and Malawi.
Predicted and observed percentage of patients with unfavorable outcome
Netherlands Vietnam Malawi
Quintiles risk score Predicted risk % Observed risk % Predicted risk % Observed risk % Predicted risk % Observed risk %
First 5 2 6 31 9 43
Second 13 14 13 40 21 64
Third 27 28 27 55 34 63
Fourth 47 52 48 70 54 70
Fifth 75 74 73 82 78 88
All patients 34 34 24 49 39 66
doi:10.1371/journal.pone.0034311.t002
Risk Prediction Bacterial Meningitis
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0.73). The ROC curves are shown in Figure 1. Calibration showed
that the Dutch model underestimated the risk of poor outcome
both in Malawi and Vietnam (Table 2). Changing the cut-of for
unfavorable outcome in Vietnam (score on mRS 0–2 vs. 3–5 or
death) did not improve performance of the risk score. The most
striking differences between predicted and observed outcome were
found in the lower risk groups. Formal goodness of fit tests clearly
confirmed the poor calibration: Vietnam, X
2=15.04, degrees of
freedom=4, p=0.005; Malawi, X
2=29.75, degrees of free-
dom=4, p,0.0001). When analyses were restricted to patients
with CSF-culture positive bacterial meningitis, the discriminative
power of the models in Vietnam (n=219; c=0.68, 95% CI 0.60–
0.74) and Malawian patients (n=300; c=0.73, 95% CI 0.67–0.79)
remained low. Analyses for patients treated with dexamethasone
and placebo showed similar results, with wider confidence
intervals.
Several coefficients from the original six predictors re-estimated
in the Malawian and Vietnamese cohorts differed markedly and
statistically significantly from the original value in the Dutch
cohort (Table 3). In Vietnam, low CSF WBC count was associated
with much lower risk of unfavorable outcome as compared with
that in the Netherlands (odds ratio [OR] 1.39, 95%CI 0.85–2.28
vs. 3.92, 95%CI 2.51–6.13; p=0.002). Also the impact of type of
bacteria seen in the Gram’s stain was significantly different
(p,0.001) in Vietnam, in particular the presence of other bacteria
was associated with a much higher risk of poor outcome than in
the Dutch population (Table 3).
In Malawi, coefficients of tachycardia (OR 0.99, 95%CI 0.53–
1.87 vs. 2.97 95%CI 1.67–5.28; p=0.01), score on the Glasgow
Coma Scale (OR 0.79, 95%CI 0.73–0.85 vs. 0.87 95%CI 0.82–
0.93; p=0.05), and bacteria seen in Gram’s stain results (p,0.001)
differed significantly with those in the Dutch population. In
Malawi, no bacteria seen with Gram’s stain was associated with
the largest increase in risk for a poor outcome, followed by having
a negative Gram’s stain. In the Dutch population, having Gram
positive cocci was associated with the largest increase in risk (see
table 3).
We also examined whether inclusion of other characteristics
would enhance discriminatory power of the nomogram. In
Vietnam, inclusion of prior antibiotic treatment would enhance
discriminatory power (OR 1.90, 95% CI 1.18–3.05, p=0.008). In
Malawi, inclusion of blood hemoglobulin concentration (OR 0.84,
95% CI 0.78–0.92, p=0.0001) and prior antibiotic treatment (OR
0.37, 95% CI 0.22–0.61, p=0.0001) would enhance discrimina-
tory power.
Discussion
Our study shows that the Dutch meningitis risk score cannot be
used to predict unfavorable outcome in middle- and low-income
countries such as Vietnam and Malawi. The discriminatory ability
of the Dutch model was substantial reduced in Vietnam and
Malawi, indicating that there is more overlap in risk scores
between patients with and without an unfavorable outcome.
Furthermore, the predicted probabilities of a poor outcome were
too low.
Several factors could have contributed to the poorer perfor-
mance of the Dutch model in these countries. Patients from
Malawi were almost uniformly HIV-infected. The high rate of
HIV infection has been associated with worse prognosis and is not
included in the risk score. [11] Second, the absence of bacteria in a
CSF Gram’s stain, a factor included in the prognostic score
associated with improved prognosis in the Netherlands, might
have the opposite effect in Malawi, as it may indicate partially
treated pneumococcal meningitis or tuberculous meningitis, which
are associated with a much poorer prognosis. [12,13] Other
factors such as suboptimal supportive health care, limited access to
health care, and differences in standards of care, i.e., nursing care,
fluid management, are also expected to limit the discriminatory
power of our model in the Malawian population. Inclusion of
blood hemoglobulin concentration, a surrogate marker of
malnutrition, and prior antibiotic treatment which was associated
with improved prognosis, [4] could enhance discriminatory power
of a multivariate prognostic model in Malawi.
In Vietnam, the majority of patients with Gram positive cocci
seen on the CSF Gram stain had meningitis due to S. suis, the
Table 3. Strength of association between predictors and poor outcome in the Dutch (original nomogram), Malawi, and
Vietnamese population.
Prognostic factors Netherlands Vietnam P-value for difference Malawi P-value for difference
OR (95% CI) OR (95% CI) P1 OR (95% CI) P2
Age, yr
a 1.24 (1.11–1.38) 1.38 (1.21–1.57) 0.23 1.16 (0.93–1.45) 0.60
Heart rate .120 beats/min 2.98 (1.68–5.29) 2.43 (0.79–7.45 0.75 0.99 (0.53–1.87) 0.01
Score on Glasgow coma scale 0.87 (0.82–0.93) 0.86 (0.80–0.93) 0.75 0.79 (0.73–0.85) 0.05
Cranial nerve palsies 2.48 (1.45–4.24) 1.23 (0.46–3.25) 0.22 1.67 (0.91–3.07) 0.34
White-cell count ,1000 per mm
3 3.92 (2.51–6.13) 1.39 (0.85–2.28) 0.002 2.65 (1.70–4.11) 0.22
Gram stain ,0.001 ,0.001
Gram positive cocci 1.00 (reference) 1.00 (reference) 1.00 (reference)
Gram negative cocci 0.27 (0.16–0.45) 0.08 (0.01–0.63) 0.17 (0.02–1.60)
Other bacteria 0.35 (0.12–1.08) 1.69 (0.56–5.10) 5.17 (1.04–25.66)
Negative 0.34 (0.18–0.64) 0.73 (0.47–1.14) 1.52 (0.93–2.49)
aOdds ratios (OR) are calculated in 10-year increments for age; P1 denotes P-value for comparison between Dutch and Vietnamese cohorts; P2 denotes P-value for
comparison between Dutch and Malawian cohorts.
Original beta’s in the Dutch cohort were: intercept=20.54; age per 1 year=0.022; increased heart rate=1.09; Glasgow Coma Scale score=20.13; cranial nerve
palsy=0.91; CSF low white cell count=1.37; gram+=reference; gram-=21.29; gram other=21.04; gram negative=21.09 The reference category for Gram’s stain has
been changed in comparison with the original publication.
doi:10.1371/journal.pone.0034311.t003
Risk Prediction Bacterial Meningitis
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[14] Reported mortality rates are lower (range 3–18%) than in
patients with other types of bacterial meningitis. [15–17] In
contrast with Malawi, prior antibiotic use was associated with
unfavorable outcome in Vietnam.
A low CSF WBC count was associated with poor outcome.
Clinical studies have shown that lower CSF WBC counts on
admission in patients with bacterial meningitis are associated with
sepsis and systemic compromise and adverse outcomes later in
disease course. [3,5,17,18] Animal studies in a pneumococcal
meningitis model showed that lower CSF WBC counts early in
disease course were associated with high bacterial load, which
correlates with intracranial complications and poor outcome. [19]
These experiments also showed that later in disease course, higher
CSF WBC counts correlated with high bacterial loads and were
associated with poor outcome.
Our study has limitations. Our validation study was based on
patients participating in a RCT where they had to meet specific
inclusion criteria suggesting that more typical meningitis patients
may have been included, and that patients at each end of the
disease spectrum (early and very advanced disease) were less
represented. This implies that the model is less suited to predict
outcome in these patients.
Our results show that the Dutch prognostic model cannot be
used accurately to predict outcome in Malawi and Vietnam. In
addition, the efficacy of adjunctive dexamethasone varied between
populations. The European trial showed a beneficial effect of
dexamethasone, [9] while the Malawi trial showed no effect, [11]
and the Vietnam trial only showed benefit in proven bacterial
meningitis cases. [10] An individual patient data meta-analysis
showed no effect when these populations were combined. [20] A
follow-up observational study in the Netherlands showed that the
introduction of adjunctive dexamethasone improved prognosis
from bacterial meningitis, an effect similar to that found in the
European RCT. [21] Meningitis populations in high, middle and
low income countries appear to be different and prognostic models
can not be used interchangeably between these populations.
Further studies of prognostic models and underlying pathogenesis
must therefore be performed in each population in order to help
design rational treatment strategies.
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